These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34400867)

  • 1. Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats.
    Bin Jardan YA; Ahad A; Raish M; Ahmad A; Alam MA; Al-Mohizea AM; Al-Jenoobi FI
    Saudi Pharm J; 2021 Jul; 29(7):719-723. PubMed ID: 34400867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats.
    Jardan YA; Brocks DR
    Biopharm Drug Dispos; 2016 Sep; 37(6):345-51. PubMed ID: 27194397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic alterations in poloxamer 407-induced hyperlipidemic rats.
    Lee U; Kwon MH; Kang HE
    Xenobiotica; 2019 May; 49(5):611-625. PubMed ID: 29658375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tolbutamide and its metabolite 4-hydroxy tolbutamide in poloxamer 407-induced hyperlipidemic rats.
    Choi MR; Kwon MH; Cho YY; Choi HD; Kim YC; Kang HE
    Biopharm Drug Dispos; 2014 Jul; 35(5):264-74. PubMed ID: 24590592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat.
    Khalil HA; Elnaggar MM; Belal TS; El-Yazbi AF; Hamdy DA
    Eur J Pharm Sci; 2016 Aug; 91():190-5. PubMed ID: 27178487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of poloxamer 407-induced hyperlipidemia on the pharmacokinetics of carbamazepine and its 10,11-epoxide metabolite in rats: Impact of decreased expression of both CYP3A1/2 and microsomal epoxide hydrolase.
    Lee YS; Kim YW; Kim SG; Lee I; Lee MG; Kang HE
    Eur Neuropsychopharmacol; 2012 Jun; 22(6):431-40. PubMed ID: 22137858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of poloxamer 407-induced hyperlipidemia on hepatic multidrug resistance protein 2 (Mrp2/Abcc2) and the pharmacokinetics of mycophenolic acid in rats.
    Kwon MH; Yoon JN; Baek YJ; Kim YC; Cho YY; Kang HE
    Biopharm Drug Dispos; 2016 Sep; 37(6):352-65. PubMed ID: 27241939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.
    Jönsson A; Rydberg T; Sterner G; Melander A
    Eur J Clin Pharmacol; 1998 Feb; 53(6):429-35. PubMed ID: 9551701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.
    Sugioka N; Haraya K; Maeda Y; Fukushima K; Takada K
    Biol Pharm Bull; 2009 Feb; 32(2):269-75. PubMed ID: 19182388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a cytochrome P450 2E1 probe, chlorzoxazone, and its 6-hydroxy metabolite in poloxamer 407-induced hyperlipidemic rats.
    Kwon MH; Lee CJ; Cho YY; Kang HE
    J Pharm Pharm Sci; 2013; 16(4):648-56. PubMed ID: 24210069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of dabigatran in a rat model of hyperlipidaemia induced by poloxamer 407.
    Kim JH; Baek E; Kang HE
    Xenobiotica; 2024 Sep; 54(9):723-729. PubMed ID: 39264043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
    Lee YS; Yoon JN; Yoon IS; Lee MG; Kang HE
    Xenobiotica; 2012 Aug; 42(8):766-74. PubMed ID: 22300394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia.
    Bouazza N; Djerada Z; Gozalo C; Busiah K; Beltrand J; Berdugo M; Urien S; Treluyer JM; Polak M
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1373-1379. PubMed ID: 27561267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of increased lipoproteins levels on the disposition of vincristine in rat.
    Khalil HA; Belal TS; El-Yazbi AF; Hamdy DA
    Lipids Health Dis; 2016 Sep; 15(1):152. PubMed ID: 27613245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models.
    Shayeganpour A; Jun AS; Brocks DR
    Biopharm Drug Dispos; 2005 Sep; 26(6):249-57. PubMed ID: 15968713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.
    Brocks DR; Ala S; Aliabadi HM
    Biopharm Drug Dispos; 2006 Jan; 27(1):7-16. PubMed ID: 16278928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins.
    Brocks DR; Wasan KM
    J Pharm Sci; 2002 Aug; 91(8):1817-26. PubMed ID: 12115809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics.
    Rydberg T; Jönsson A; Karlsson MO; Melander A
    Br J Clin Pharmacol; 1997 Apr; 43(4):373-81. PubMed ID: 9146849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat.
    Eliot LA; Foster RT; Jamali F
    Pharm Res; 1999 Feb; 16(2):309-13. PubMed ID: 10100319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat.
    Hamdy DA; Brocks DR
    J Pharm Sci; 2011 Nov; 100(11):4986-92. PubMed ID: 21698600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.